Pathological and clinical assessments revealed no significant differences between LOADS1 and LOAD-S2 in terms of APOE status, polygenic risk scores for AD, age of onset, last cognitive assessment, or key measures of NFT and amyloid pathology (Supplementary Table 22). This evidence concerns the gene APOE and Alzheimer disease.